Objective. To describe a subset of cases in a large cohort of patients with primary CNS vasculitis (PCNSV) who appear to have a rapidly progressive clinical course.
Introduction
Primary CNS vasculitis (PCNSV) is an uncommon condition that affects the brain and spinal cord [1, 2] . It is heterogeneous in presenting characteristics and therapeutic requirements [3] [4] [5] [6] [7] . PCNSV has been considered a lifethreatening condition and cases with a progressive and fatal course despite the aggressive immunosuppressive therapy were described in the early studies [2, 8, 9] .
Recently, we reported 101 patients with PCNSV seen at Mayo Clinic (Rochester, MN, USA) over a 21-year period [1] . Most patients showed a favourable response to glucocorticoids alone or in combination with CYC. However, we observed an overall increased mortality rate. This appeared to reflect the presence of a subgroup of patients with more serious and widespread neurological lesions that were associated with a poor outcome despite the treatment.
In the present study, we have extended the previous cohort of PCNSV patients to include the period 2004-07. The aim of this study was to assess the clinical characteristics of PCNSV patients with rapidly progressive disease in the enlarged 1983-2007 cohort. The modified Rankin scale was used to identify this subgroup [10] . We compared the clinical features of these patients with those of the other PCNSV patients without a rapidly progressive course to define potential findings that identified this subset of patients to permit early recognition and aggressive treatment.
Patients and methods

Patients
For this study, we extended our earlier PCNSV cohort of 101 consecutive patients seen at Mayo Clinic (Rochester, MN, USA) over the 21-year period 1983 through 2003 to 25 years, 1983 through 2007 [1] . The same method of case ascertainment was used to expand this cohort to include all cases of PCNSV treated at Mayo Clinic from 1 January 2004 through 31 December 2007. Patients were considered to have definite PCNSV if a brain or spinal cord biopsy specimen showed vasculitis (transmural destructive inflammatory infiltrate) or if angiograms showed changes that were highly suggestive of vasculitis (segmental narrowing, dilatation or occlusion affecting multiple cerebral arteries in the absence of proximal vessel changes of atherosclerosis) [1, 11] . Angiograms were also divided into two groups: large artery (intracranial internal carotid and vertebral arteries, basilar artery and proximal anterior, middle and posterior cerebral arteries) and small artery (intracranial artery, second division branches or smaller). We excluded patients with vasculitis in organs other than the CNS and those with evidence of other diseases such as SLE and infection. None of the patients had a history of thunderclap headache, exposure to vasoactive substances, migraine headaches, subarachnoid haemorrhage or other evidence of reversible cerebral vasoconstriction syndrome [12] . During the recent review period, 30 additional cases fulfilled the diagnostic criteria for PCNSV. Therefore, from 1983 to 2007, 131 patients with PCNSV were seen at Mayo Clinic (Rochester, MN, USA). The Mayo Clinic Institutional Review Board (IRB) approved this study. Informed consent was not obtained for this study. The Mayo Clinic IRB reviewed and approved the study. The IRB approved waiver of specific informed consent in accordance with 45 Code of Federal Regulations 46.116 (d) as justified by the investigator, and waiver of Health Information Portability and Accountability Act (HIPAA) authorization in accordance with applicable HIPAA regulations.
Biopsy specimens were reviewed by two pathologists (D.V.M. and C.G.) and angiograms were reviewed by a neuroradiologist. In cases with an uncertain initial diagnosis, the complete medical record was reviewed again by two rheumatologists (C.S. and G.G.H.) and one neurologist (R.D.B.) to reach a consensus. A standard data collection form was completed for all cases. It included comprehensive information about clinical manifestations at presentation and during the follow-up, other medical conditions, laboratory investigations, radiological imaging, results of CNS biopsy or autopsy, response to treatment, number of relapses, follow-up functional status and cause of death. To assess the effect of treatment, we used the treating physician's global opinion about the response to therapy.
The modified Rankin scale [10] was used to evaluate the functional status at presentation and at the last visit. It is a standardized and commonly used scale that measures disability or dependence in activities of daily living in stroke victims. The scale consists of seven scores: 0 corresponds to no signs or symptoms; 1: no significant disability, despite symptoms; 2: slight disability; 3: moderate disability; 4: moderately severe disability; 5: severe disability; and 6: death. The modified Rankin scale was used to identify rapidly progressive disease: patients with Rankin 5 (severe disability) or 6 (death) at diagnosis or Rankin 5 or 6 at last follow-up (patients with Rankin <5 at diagnosis must develop a score of 5 or 6 within 6 months after the diagnosis).
Vasculitis was found in 41 of 63 CNS tissue specimens taken for diagnosis (Table 1) . A granulomatous inflammatory histological pattern was found in 23 patients (accompanied by vascular deposits of amyloid b-peptide in 11), a granulomatous and necrotizing pattern in 1, an acute necrotizing pattern in 9 and a lymphocytic pattern in 8. Changes of vasculitis were found in 97 (90.7%) of 107 angiograms. Angiograms alone were used to confirm the diagnosis in not only 90 patients, but were also positive in seven additional patients whose brain biopsy showed vasculitis.
Statistical analysis
Differences between the patients with rapidly progressive PCNSV and those with PCNSV but without rapidly progressive disease were tested with two-sided Wilcoxon rank-sum tests for numeric characteristics and Fisher's exact tests for categorical characteristics. Significance was defined at P < 0.05.
Results
Demographic and clinical features
Eleven of the 131 patients (8.4%) had a rapidly progressive disease course. The demographic characteristics and clinical symptoms of these 11 patients are compared with those of the other 120 patients in Table 1 and are summarized individually in Table 2 . Five of the 11 were males. The median age at diagnosis was 58.0 years (range 38-74 years). The disease tended to be rapidly progressive after onset. The time from onset of symptoms to diagnosis was 41 month in six patients (54.5%), with a median of 24 days (range 6-167 days). Cognitive dysfunction, persistent neurological deficit and headache were the most common symptoms at presentation. Four patients had a sudden change in the level of consciousness and another four patients had a progressive and dramatic cognitive decline.
An acute paraparesis or quadriparesis was observed in four patients. Constitutional symptoms such as fever were present only in two patients; however, in one patient, fever was secondary to the presence of pneumonia. Symptoms related to spinal cord involvement occurred in one patient (Patient 4) simultaneously with brain involvement. Other medical disorders were noted in five patients, including diabetes [4] , hypertension [3] and myasthenia gravis [1] . ). ESRs were normal in six of the nine patients who had ESR determination (median rate 20 mm/h; range 4-61 mm/h). ANCAs and aPLs (LA and/or aCLs and/or anti-b2-glycoprotein I antibodies) were tested in seven patients and were negative in all of them. Tables 2 and 3 show the neuroimaging findings at presentation. Brain MRI with and without contrast medium was performed in 10 of the 11 patients. Infarctions were seen in all 10 patients (Fig. 1) . Multiple infarctions were found in nine patients (90%). Of these nine patients, lesions were bilateral in 8 (89%) and involved both the cortex and subcortex in 7 (78%). None had intracerebral haemorrhage. One patient had meningeal enhancement. Diagnostic CT scans were performed in the patient without MRI. Multiple bilateral infarcts and intracerebral haemorrhage were observed in this patient.
Laboratory investigations
Radiological imaging
Cerebral angiography was performed in 10 of the 11 patients, and all 10 showed changes characteristic of vasculitis. Multiple-vessel bilateral abnormalities were found in all 10 patients. All 10 had large-vessel involvement (Fig. 1) ; however, nine also had small-vessel abnormalities, which were bilateral in eight patients. Patient 10 had a second angiogram 5 months after the onset of the therapy. There was progression in cerebral lesions with development of new stenoses.
Magnetic resonance angiography (MRA) was performed in 6 of the 11 patients. Results were suggestive of bilateral multiple-vessel vasculitis in four patients and were normal in two patients. Conventional angiography also was performed in five of the six patients. In one patient, MRA showed normal findings, but conventional angiograms suggested vasculitis. Thus, conventional angiography and MRA yielded the same results for four of five patients (80%).
Biopsy results Table 1 summarizes the pathology results. Three open brain biopsies were performed, and one showed evidence of vasculitis. In two other patients, evidence of vasculitis was found in post-mortem specimens (Fig. 2) . In one of these two patients, only the brain was involved, whereas in the second, both brain and spinal cord revealed vasculitic lesions. In conclusion, histological evidence of vasculitis was observed in three patients. One patient each had an inflammatory infiltration showing a granulomatous and necrotizing pattern, a necrotizing pattern and a granulomatous pattern. The inflammation was markedly angiocentric and involved mainly leptomeningeal vessels in all three patients. Vascular deposits of amyloid b-peptide were present in one patient. Evidence of multiple cerebral infarcts was present in all three patients, while one also had evidence of ischaemic infarcts of the spinal cord.
Treatment and outcome
The details of treatment, follow-up MRI and the status of patients at their last visit are shown in Table 4 . The median duration of follow-up was 157 days (range 17-545 days). Nine patients were treated with daily prednisone. The median starting dosage of oral prednisone therapy was 60 mg/day (range 16-150 mg/day). The median duration of oral prednisone therapy was 5.2 months (range 0.5-14 months). In six patients (Patients 1, 5, 7, 8, 10 and 11), oral prednisone treatment was preceded by methylprednisolone pulse therapy (three patients received 500 mg/day for 4, 5 and 9 days, respectively; two patients received 1 g/day for 3 days and 1 for 4 days). Additionally, two other patients received i.v. dexamethasone. Patients 2 and 4 were initially treated with dexamethasone pulse therapy (190 and 96 mg/day for 3 days, respectively), then the dosage was reduced to 10 mg/day for 4 days and 16 mg/day for 10 days, respectively. The only available brain MRI was performed at Mayo Clinic 5 months after the diagnosis and the onset of therapy (see Table 4 for details on follow-up MRI). TIA: transient ischaemic attack; ACA: anterior cerebral artery; MCA: middle cerebral artery; PCA: posterior cerebral artery; F: female; M: male.
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Three patients (Patients 2, 3 and 9) initially were treated with CSs only, and eight were treated with CSs and immunosuppressive agents. Five patients (Cases 1, 5, 6, 7 and 8) received daily oral doses of CYC, and one patient (Patient 10) received both monthly i.v. CYC pulse therapy and daily oral CYC at different times during the disease course. The median duration of CYC treatment was 3.5 months (range 0.5-11 months). Two patients (Patients 4 and 11) received AZA for 13 days and 4 months, respectively. Three sessions of plasma exchange were performed in one patient (Patient 8).
The outcome was poor for all the patients. Six patients (Patients 2, 3, 4, 5, 8 and 9) had a rapid and fatal clinical course despite the aggressive treatment. Their neurological status progressively deteriorated and they died after a median of 16 days (range 7-30 days) from the onset of the immunosuppressive treatment. Four patients (Patients 1, 7, 10 and 11) had a less aggressive course. Patients 7 and 10 died from cerebral ischaemic involvement 11 months and 6.5 months after starting treatment, respectively.
Patient 7 was initially treated with methylprednisolone pulse therapy, oral prednisone and oral CYC. However, her neurological status did not improve, and on two occasions when oral prednisone was reduced from 80 to 60 mg/day she had relapses. In both relapses, an increased dosage of oral prednisone to 80 mg/day did not result in improvement. Follow-up brain MRI performed showed new ischaemic lesions involving the pons and she died in coma while she was taking prednisone 80 mg/day and CYC 125 mg/day.
Patient 10 was initially treated with methylprednisolone pulse therapy, oral prednisolone and oral CYC. She had a partial improvement in her neurological status; however, she had a relapse as her oral prednisone and CYC dosages were being reduced after 4.5 months of treatment. A control cerebral angiogram showed the development of new vasculitic lesions. Oral prednisone dosage was increased to 60 mg/day and one pulse i.v. injection of CYC was administered; however, her neurological status rapidly deteriorated and she died 2 months later. Followup brain MRI showed new subacute infarcts involving the left frontal and occipital lobes and the right inferior cerebellum.
Patients 1 and 11 died from aspiration pneumonia. In Patient 1, the immunosuppressive treatment was suspended after 3 months for the lack of improvement of his comatose status. The patient died 1 year later remaining in coma during the follow-up. Patient 11 was initially treated with methylprednisolone pulse therapy, oral prednisone and AZA. However, his neurological status did not improve. Four months later when AZA was suspended he had a relapse. CS therapy was increased; however, his neurological status deteriorated and he died 1 month later. Follow-up brain MRI showed new subacute infarcts involving the corpus callosum and the left parieto-occipital and parasagittal frontal lobes.
Patient 6 was the only one to be alive at the end of follow-up. His neurological presenting status continued to deteriorate for the first 2 months after the beginning of oral prednisone and CYC, and then stabilized. At his final follow-up visit 12 months later, he was still receiving immunosuppressant therapy and he had very severe disability being completely blind, bilaterally hemiparetic, bedridden, incontinent and requiring constant nursing care and attention. In summary, all 11 patients failed to respond to aggressive immunosuppressive therapy. The neurological course was acute/subacute in most of them. Stroke was the cause of death in eight of the patients, while two died for aspiration pneumonia, a final event strictly associated to their deteriorated neurological status. The only patient alive at the end of follow-up period had a fixed major neurological dysfunction (modified Rankin score 5). Follow-up MRI studies were available in six patients, and new extensive infarcts were observed in five patients despite the treatment.
Comparison of patients with and without rapidly progressive disease
The 11 cases with rapidly progressive PCNSV are compared with the 120 cases without rapidly progressive disease in Tables 1 and 3 . This showed that the presence of paraparesis or quadriparesis at presentation (36.4 vs 2.5%; P = 0.001), angiographic evidence of bilateral, large-vessel vasculitis (100 vs 52.9%; P = 0.004) and MRI evidence of cerebral infarctions (100 vs 50.5%, P = 0.002) were significantly more frequent in patients with rapidly progressive PCNSV than in the others. Furthermore, in those with rapidly progressive PCNSV, cerebral infarctions were more frequently multiple and bilateral (80.0 vs 36.9%; P = 0.015) and more frequently involved both the cortex and subcortical regions on initial MRI (70.0 vs 25.2%; P = 0.006). ESR values at diagnosis were significantly higher in patients with rapidly progressive disease (P = 0.049) possibly reflecting a more intense and diffuse inflammation of cerebral vessels.
Other differences in those with rapidly progressive PCNSV that were not statistically significant included a higher median age at diagnosis, shorter median period between onset of symptoms to diagnosis, a higher frequency of persistent neurological deficit or stroke at presentation, a lower frequency of parenchymal and/or meningeal gadolinium-enhancing lesions at MRI and a lower frequency of patients not requiring therapy at last follow-up. More patients with rapidly progressive disease were treated initially with CYC or AZA and less frequently with CSs only.
ANCAs were tested in 83 patients and were negative in all of them. aPLs (LA and/or aCL and/or antib2-glycoprotein I antibodies) were measured in 81 patients and were positive in only 1 patient without rapidly progressive course.
Discussion
In our previous analysis of 101 patients with PCNSV who were seen at our institution over a 21-year period, we noted that despite a favourable response to immunosuppressive treatment in most patients, the survival of the overall cohort was significantly reduced [1] . The reduced survival rate was due to five patients who died from cerebral infarctions within the first year of follow-up. These patients seemed to have a more aggressive and serious disease that was less responsive to the treatment. Because early recognition and treatment of these patients may help avoid poor outcomes, we decided to attempt to better define the subset of patients with a rapidly progressive course. For this analysis, we extended the previous cohort of PCNSV patients to a 25-year period, 1983 www.rheumatology.oxfordjournals.org through 2007, which included a total of 131 patients. The modified Rankin scale was used to identify this subgroup from the total population [10] . This scale is commonly used to measure disability or dependence in activities of daily living in stroke victims. The scale consists of seven grades, from 0 to 6, with 0 corresponding to no symptoms and 6 corresponding to death. Severe disability or death at diagnosis or at last follow-up were selected as criteria to identify the patients with rapidly progressive disease. Furthermore, because rapidly progressive should be a condition presenting over a relatively short period of time, we included only those patients with Rankin <5 at diagnosis who develop severe disability or died within 6 months after the diagnosis.
To determine whether the 11 patients had clinical characteristics that distinguished them from the other patients without a rapidly progressive course, we compared the two groups. The results suggested that those with a rapidly progressive course represent a subgroup at the worst end of the clinical spectrum of PCNSV. They had several different features including a statistically significant higher frequency of paraparesis or quadraparesis at presentation, angiographic evidence of bilateral, larger vessel vasculitis and MRI evidence of cerebral infarction. Furthermore, in the patients with rapidly progressive disease the cerebral infarctions were significantly more frequently multiple and bilateral, and more frequently involved both the cortex and subcortex on initial MRI.
Although ESR values at diagnosis were significantly higher in this subset of PCNSV patients, the differences were small and not likely to be helpful in identifying individual patients with a rapidly progressive course.
Other differences in those with rapidly progressive PCNSV that were not statistically significant, perhaps because of small numbers, included a higher median age at diagnosis, shorter median period between onset of symptoms and diagnosis, higher frequency of a persistent neurological deficit or stroke at presentation, lower frequency of parenchymal and/or meningeal gadolinium enhancement on MRI, more frequent initial treatment with CYC or AZA, and lower frequency of patients suspending therapy during follow-up. Furthermore, in the patients with rapidly progressive disease we observed only a granulomatous and/or necrotizing histopathological pattern, but none with a lymphocytic pattern. CSF findings were generally mild and non-specific.
The clinical presenting neurological symptoms, the neuroimaging findings and the rapidly progressive disease course observed in these patients clearly differentiate them from two other recently described PCNSV subsets [3, 4] . The first was defined by the presence on MRI of prominent gadolinium leptomeningeal enhancement, The modified Rankin score is defined as follows: 0: no signs or symptoms of disability; 1: no significant disability, despite symptoms; 2: slight disability; 3: moderate disability; 4: moderately severe disability; 5: severe disability; 6: death.
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www.rheumatology.oxfordjournals.org while the second was delineated by patients with a normal cerebral angiogram, but a brain biopsy positive for vasculitis. Both subsets were characterized by small-vessel involvement beyond the resolution of conventional angiography. Both also had a rapid response to the treatment with a favourable neurological outcome. In both subsets, no patients died for vasculitis-related causes. However, these two subsets also presented some differences. The first was associated with amyloid angiopathy, while the second more frequently had cognitive dysfunction at presentation and marked elevations of CSF total protein level. The size of the vessels involved in PCNSV confers heterogeneity to the syndrome [5] . Our results indicated that multiple, bilateral involvement of large vessels define a rapidly progressive subset of PCNSV manifested by multiple recurrent cerebral infarctions affecting different vessel territories. The disease progression was most commonly rapid and led to a fatal outcome despite treatment with high doses of CSs. Eight patients also received additional immunosuppressive agents (CYC and AZA) and one three sessions of plasma-exchange. There was no apparent response to these aggressive regimens and follow-up MRI usually showed disease progression with the development of new subacute infarcts. A second angiogram in one patient demonstrated progression of vasculitic lesions that paralleled the worsening of a follow-up MRI.
A strength of this study is the identification of a clinical subset of patients with rapidly progressive PCNSV who were members of a large cohort of consecutive patients with PCNSV reported from a single institution, with well-defined and uniform case ascertainment and clinical follow-up. Limitations of the study include its retrospective nature, a potential selection bias and lack of tissue diagnosis in the majority of cases even though the angiograms were highly indicative of vasculitis and there was no evidence of any other condition than vasculitis at presentation or during the course of the illness.
TNF-a blockade was effective in two patients with PCNSV that was refractory to combined immunosuppressive treatment [13] . In view of the poor response to the traditional immunosuppressive therapy observed in patients with rapidly progressive course and in the absence of evidence from controlled study, a trial of daily pulse steroids for several days and biologic therapies should be considered in similar cases. Although a prospective multicentre study would be the only way to gain clear objective information about the efficacy of currently available therapies in PCNSV, the rarity of this condition makes this improbable.
In conclusion, rapidly progressive PCNSV represents the worst end of the clinical spectrum of PCNSV. These patients have a rapidly progressive disease course with often fatal outcome. They are characterized by bilateral, multiple, large cerebral vessel lesions on angiograms and multiple bilateral cerebral infarctions frequently involving both the cortex and subcortex. The predominant vasculitic histopathological pattern is granulomatous and/or necrotizing. These patients have also higher levels of ESR and respond poorly to the traditional immunosuppressive treatment. New therapeutic options for this subset of patients are needed.
Rheumatology key messages
. Rapidly progressive PCNSV represents the worst end of the clinical spectrum of PCNSV. . The diagnosis of rapidly progressive PCNSV requires a high degree of clinical awareness.
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